Database Query Results : , , FASN

FASN, Fatty acid synthase: Click to Expand ⟱
Source:
Type:
Fatty acid synthase (FASN) is an enzyme involved in the synthesis of fatty acids, which are essential for cell growth and proliferation. Overexpression of FASN has been observed in various types of cancer, and it is often associated with poor prognosis.
-fatty acid synthase (FAS) has been demonstrated to play an important role in carcinogenesis by protecting cells from apoptosis

FASN (fatty acid synthase) is a key enzyme in the de novo synthesis of fatty acids and has been widely studied in cancer due to its role in lipid metabolism and energy production. Altered FASN expression has been reported in various malignancies, and its prognostic implications have been explored across several tumor types.

FASN is frequently overexpressed in a variety of cancers, including breast, prostate, colorectal, ovarian, and others.
• Many cancers require high levels of fatty acid synthesis for the generation of new membranes and for signaling lipid molecules.
• Higher FASN expression is generally associated with more aggressive cancer phenotypes, increased metastatic potential, and poorer patient outcomes.
• Its role in promoting de novo fatty acid synthesis links it directly to the metabolic demands of rapidly dividing cancer cells, making it both a prognostic biomarker and a promising therapeutic target.
Scientific Papers found: Click to Expand⟱
1252- aLinA,    α-Linolenic acid induces apoptosis, inhibits the invasion and metastasis, and arrests cell cycle in human breast cancer cells by inhibiting fatty acid synthase
- in-vitro, BC, NA
FASN↓, Apoptosis↑, TumCI↓, TumMeta↓, TumCCA↑,
1253- aLinA,    The Antitumor Effects of α-Linolenic Acid
- Review, NA, NA
PPARγ↑, COX2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,
1007- And,    In vitro and in silico evaluation of Andrographis paniculata ethanolic crude extracts on fatty acid synthase expression on breast cancer cells
- in-vitro, BC, MCF-7 - in-vitro, BC, EMT6
tumCV↓, i-FASN↓,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
1172- Ash,    Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
FASN↓, ACLY↓, ACC1↓, CPT1A↓, SREBP1↓,
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoPv↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,
2740- BetA,    Effects and mechanisms of fatty acid metabolism-mediated glycolysis regulated by betulinic acid-loaded nanoliposomes in colorectal cancer
- in-vitro, CRC, HCT116
TumCP↓, Glycolysis↓, HK2↓, PFK1↓, PKM2↓, ACSL1↓, CPT1A↓, FASN↓, FAO↓, GlucoseCon↓, lactateProd↓,
3521- Bor,    A new hope for obesity management: Boron inhibits adipogenesis in progenitor cells through the Wnt/β-catenin pathway
- in-vitro, Obesity, 3T3
*CEBPA↓, *PPARγ↓, *FASN↓, *SREBP1↓, *FABP4↓, *GLUT4↓, *β-catenin/ZEB1↑, *MMP2↓, *FGF↑, *Ca+2?,
1640- CA,  MET,    Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines
- in-vitro, Cerv, SiHa
GLS↓, NADPH↓, ROS↑, TumCD↑, AMPK↑, Hif1a↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDH↓, cMyc↓, BAX↓, cycD1/CCND1↓, PDH↓, ROS↑, Apoptosis↑, eff↑, ACLY↓, FASN↓, Bcl-2↓, Glycolysis↓,
2348- CAP,    Recent advances in analysis of capsaicin and its effects on metabolic pathways by mass spectrometry
- Analysis, Nor, NA
Warburg↓, *PKM2↓, *COX2↓, *Inflam↓, *Sepsis↓, *AMPK↑, *PKA↑, *mitResp↑, *FAO↑, *FASN↓, *PGM1?, *ATP↑, *ROS↓,
1576- Citrate,    Targeting citrate as a novel therapeutic strategy in cancer treatment
- Review, Var, NA
TCA↓, T-Cell↝, Glycolysis↓, PKM2↓, PFK2?, SDH↓, PDH↓, β-oxidation↓, CPT1A↓, FASN↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, cl‑PARP↑, Hif1a↓, GLUT1↓, angioG↓, Ca+2↓, ROS↓, eff↓, Dose↓, eff↑, Mcl-1↓, HK2↓, IGF-1R↓, PTEN↑, citrate↓, Dose∅, eff↑, eff↑, eff↑, eff↑,
1578- Citrate,    Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update
- Review, Var, NA
TCA↑, FASN↑, Glycolysis↓, glucoNG↑, PFK1↓, PFK2↓, FBPase↑, TumCP↓, eff↑, ACLY↓, Dose↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, Bcl-xL↓, Mcl-1↓, IGF-1R↓, PI3K↓, Akt↓, mTOR↓, PTEN↑, ChemoSen↑, Dose?,
2308- CUR,    Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells
- in-vitro, Liver, HepG2
GlucoseCon↓, lactateProd↓, ECAR↓, NO↓, ROS↑, HK2↓, PFK1↓, GAPDH↓, PKM2↓, LDHA↓, FASN↓, GLUT1↓, MCT1↓, MCT4↓, HCAR1↓, SDH↑, ChemoSen↑, ROS↑, BioAv↑, P53↑, NF-kB↓, pH↑,
2305- CUR,    Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN
- in-vitro, BC, MCF-7
BioAv↑, PKM2↓, FASN↓, Glycolysis↓,
1035- DHA,    Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation
- vitro+vivo, NA, NA
PD-L1↓, FASN↓,
1322- EMD,    The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers
- Review, Var, NA
Apoptosis↑, TumCP↓, ROS↑, TumAuto↑, EMT↓, TGF-β↓, DNAdam↑, ER Stress↑, TumCCA↑, ATP↓, NF-kB↓, CYP1A1↑, STAC2↓, JAK↓, PI3K↓, Akt↓, MAPK↓, FASN↓, HER2/EBBR2↓, ChemoSen↑, eff↑, ChemoSen↑, angioG↓, VEGF↓, MMP2↓, eNOS↓, FOXD3↑, MMP9↓, TIMP1↑,
1086- GA,    Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation
- in-vitro, AML, K562
tumCV↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Cyt‑c↑, cl‑PARP↓, DNAdam↑, Casp3↑, FASN↓, Casp8↑,
1186- Gb,    Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis
- in-vitro, PC, NA - in-vitro, Nor, HUVECs - in-vivo, PC, NA
tumCV↓, *toxicity∅, TumCMig↓, TumCI↓, Apoptosis↑, AMPK↑, lipoGen↓, ACC↓, FASN↓,
1630- HCA,    Chemistry and biochemistry of (-)-hydroxycitric acid from Garcinia
- Review, NA, NA
ACLY↓, FASN↓, lipoGen↓, Weight↓,
1200- LT,    Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation
- in-vitro, Pca, DU145
FASN↓, cMET↓, HGF/c-Met↓,
2906- LT,    Luteolin, a flavonoid with potentials for cancer prevention and therapy
- Review, Var, NA
*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,
3268- Lyco,    Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders
- Review, AD, NA
*BioAv↓, *AntiCan↑, *ROCK1↓, *Ki-67↓, *ICAM-1↓, *cardioP↑, *antiOx↑, *NQO1↑, *HO-1↑, *TNF-α↓, *IL22↓, *NRF2↑, *NF-kB↓, *MDA↓, *Catalase↑, *SOD↑, *GSH↑, *cognitive↑, *tau↓, *hepatoP↑, *MMP2↑, *AST↓, *ALAT↓, *P450↑, *DNAdam↓, *ROS↓, *neuroP↑, *memory↑, *Ca+2↓, *Dose↝, *Dose↑, *Dose↝, *toxicity∅, PGE2↓, CDK2↓, CDK4↓, STAT3↓, NOX↓, NOX4↓, ROS↓, *SREBP1↓, *FASN↓, *ACC↓,
1182- MushCha,    Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the β-catenin pathway in colorectal cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT-29 - in-vitro, CRC, SW-620 - in-vitro, CRC, DLD1
Apoptosis↑, TumCG↓, FASN↓, β-catenin/ZEB1↓, cMyc↓, cycD1/CCND1↓, CDK8↓, Ki-67↓,
1229- OA,    Review of the Clinical Effect of Orlistat
- Review, NA, NA
NPC1L1↓, FASN↓, ER Stress↑, angioG↓, TumCG↓,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
4626- OLE,    A Comprehensive Review on the Anti-Cancer Effects of Oleuropein
- Review, Var, NA
Risk↓, Dose↑, TumCP↓, NF-kB↓, COX2↓, Akt↓, P53↑, BAX↑, Bcl-2↓, HIF-1↓, ROS↑, HO-1↑, chemoP↑, TumCCA↑, FASN↓,
1226- OLST,    Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation
- vitro+vivo, GC, NA
PGM1∅, FASN↓, Apoptosis↑, lipidLev↑, GlucoseCon↑, eff↑,
1045- OLST,    Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line
- in-vitro, AML, Jurkat
FASN↓, TumCG↓, PD-L1↓,
969- OLST,    Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy
- Review, NA, NA
FASN↓,
1231- PBG,    Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, MMP↓, TLR4↓, TNF-α↓, NF-kB↓, IL1β↓, IL6↓, IRAK4↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ACC↓, FASN↓, eff↓,
1237- PTS,    Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade
- in-vitro, Ovarian, SKOV3
TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,
3354- QC,    Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine
- Review, Var, NA
*ROS↓, *IronCh↓, *lipid-P↓, *GSH↑, *NRF2↑, TumCCA↑, ER Stress↑, P53↑, CDK2↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, cycD1/CCND1↓, PCNA↓, P21↑, p27↑, PI3K↓, Akt↓, mTOR↓, STAT3↓, cFLIP↓, cMyc↓, survivin↓, DR5↓, *Inflam↓, *IL6↓, *IL8↓, COX2↓, 5LO↓, *cardioP↑, *FASN↓, *AntiAg↑, *MDA↓,
3381- QC,    Quercetin induces cell death in cervical cancer by reducing O-GlcNAcylation of adenosine monophosphate-activated protein kinase
- in-vitro, Cerv, HeLa
SREBP1↓, TumCP↓, TumCD↑, AMPK↑, SREBP1↓, FASN↓, ACC↓,
2984- RES,    Involvement of miR-539-5p in the inhibition of de novo lipogenesis induced by resveratrol in white adipose tissue
- in-vivo, Nor, NA
*Sp1/3/4↓, *SREBP1↓, *FASN↓,
3094- RES,    Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
CSCs↓, tumCV↓, FASN↑, BNIP3↑, *cardioP↑, *antiOx↑, NF-kB↓, COX2↓, MMP9↓, IGF-1↓, ERK↓, lipid-P↓, CD24↓,
1251- RT,  OLST,    Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions
- in-vitro, BC, MCF-7 - in-vitro, PC, PANC1 - in-vivo, NA, NA
TumVol↓, *CEA↓, *FASN↓, *ROS↓, *MDA↓, *GSH↑, Apoptosis↑,
3200- SFN,    Sulforaphane suppresses the activity of sterol regulatory element-binding proteins (SREBPs) by promoting SREBP precursor degradation
- in-vitro, Liver, HUH7
FASN↓, ACC↓, SREBP1↓,
2404- SFN,    Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism
- in-vitro, Pca, LNCaP - in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
ACC1↓, FASN↓, CPT1A↓, β-oxidation↓, SREBP1?, HK2↓, PKM2↓, LDHA↓, Glycolysis↓,
3294- SIL,    Silymarin: a review on paving the way towards promising pharmacological agent
- Review, Nor, NA - Review, Arthritis, NA
*hepatoP↑, *Inflam↓, *chemoP↑, *glucose↓, *antiOx↑, *ROS↓, *ACC↓, *FASN↓, *radioP↑, *NF-kB↓, *TGF-β↓, *AST↓, *α-SMA↝, *eff↑, *neuroP↑, eff↑, ROS↓,
964- SIL,    Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, 22Rv1
TumCP↓, Hif1a↓, NADPH↓, angioG↓, FASN↓, ACC↓,
2356- SK,    ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment
- in-vitro, Ovarian, CaOV3 - in-vitro, Ovarian, OV90 - in-vivo, NA, NA
PKM2↓, Glycolysis↓, FASN↓, lactateProd↓, Warburg↓, TumCG↓, VM↓,
2411- UA,    Ursolic acid in health and disease
- Review, Var, NA
Inflam↓, antiOx↑, NF-kB↓, Bcl-xL↓, Bcl-2↓, cycD1/CCND1↓, Ki-67↓, CD31↓, STAT3↓, EGFR↓, P53↑, P21↓, HK2↓, PKM2↓, ATP↓, lactateProd↓, p‑ERK↓, MMP↓, NO↑, ATM↑, Casp3↑, AMPK↑, JNK↑, FAO↑, FASN↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑, neuroP↑,
4328- VitB5,    Pantethine
- Review, AD, NA
*BBB↝, *LDL↓, *lipid-P↓, *AST↓, *ALAT↓, *TGF-β↓, *adiP↑, *Inflam↓, TumCG↓, FASN↓,
3140- VitC,    Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest
- in-vitro, PC, MIA PaCa-2 - in-vitro, Nor, HEK293
citrate↓, FASN↓, ACLY↓, LDH↓, Glycolysis↓, Warburg↓, PDK1↓, GLUT1↓, LDHA↓, ECAR↓, PDH↑, eff↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 44

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 1,   antiOx⇅, 1,   Catalase↓, 1,   CYP1A1↓, 1,   CYP1A1↑, 1,   HO-1↑, 2,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↑, 1,   NOX4↓, 1,   NOX4↑, 1,   NQO1↑, 1,   NRF2↑, 1,   OXPHOS↓, 1,   ROS↓, 4,   ROS↑, 11,   ROS⇅, 1,   SIRT3↓, 1,   SOD2↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 2,   MMP↓, 4,   MPT↑, 1,   SDH↓, 1,   SDH↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 5,   ACC1↓, 2,   ACLY↓, 6,   ACSL1↓, 1,   AMPK↓, 1,   AMPK↑, 5,   p‑AMPK↑, 1,   citrate↓, 2,   cMyc↓, 3,   CPT1A↓, 4,   ECAR↓, 2,   FAO↓, 1,   FAO↑, 1,   FASN↓, 33,   FASN↑, 3,   i-FASN↓, 1,   FBPase↑, 1,   GAPDH↓, 1,   GLS↓, 1,   glucoNG↑, 1,   GlucoseCon↓, 2,   GlucoseCon↑, 1,   Glycolysis↓, 8,   HK2↓, 7,   lactateProd↓, 4,   LDH↓, 3,   LDHA↓, 4,   lipidLev↑, 1,   lipoGen↓, 2,   MCT4↓, 1,   NADPH↓, 2,   NPC1L1↓, 1,   PDH↓, 2,   PDH↑, 1,   PDK1↓, 1,   PFK↓, 2,   PFK1↓, 3,   PFK2?, 1,   PFK2↓, 1,   PGM1∅, 1,   PKM2↓, 9,   PPARγ↑, 2,   p‑S6K↓, 1,   SREBP1?, 1,   SREBP1↓, 5,   TCA↓, 1,   TCA↑, 1,   Warburg↓, 3,   β-oxidation↓, 2,  

Cell Death ⓘ

Akt↓, 8,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↑, 10,   BAD↑, 1,   Bak↑, 1,   BAX↓, 1,   BAX↑, 4,   Bax:Bcl2↑, 2,   Bcl-2↓, 8,   Bcl-xL↓, 3,   Casp↑, 3,   Casp2↑, 2,   Casp3↑, 8,   cl‑Casp3↑, 1,   cl‑Casp7↑, 1,   Casp8↑, 3,   cl‑Casp8↑, 1,   Casp9↑, 3,   cl‑Casp9↑, 1,   cFLIP↓, 1,   CK2↓, 2,   Cyt‑c↑, 4,   DR5↓, 1,   DR5↑, 1,   Fas↑, 1,   HGF/c-Met↓, 1,   cl‑IAP2↑, 1,   iNOS↓, 1,   JNK↑, 3,   p‑JNK↓, 1,   MAPK↓, 2,   Mcl-1↓, 2,   MCT1↓, 1,   p27↑, 4,   p38↓, 1,   survivin↓, 1,   Telomerase↓, 1,   TumCD↑, 2,  

Kinase & Signal Transduction ⓘ

FOXD3↑, 1,   HER2/EBBR2↓, 2,   p‑TSC2↑, 1,  

Transcription & Epigenetics ⓘ

p‑pRB↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 4,   HSP90↓, 1,   HSPs↓, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

ATM↑, 1,   DNAdam↑, 2,   P53↓, 1,   P53↑, 7,   p‑P53↑, 1,   PARP↑, 1,   cl‑PARP↓, 1,   cl‑PARP↑, 2,   PCNA↓, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 3,   CDK4↓, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 2,   P21↓, 1,   P21↑, 5,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State ⓘ

p‑4E-BP1↓, 1,   CD24↓, 1,   CDK8↓, 1,   cMET↓, 1,   CSCs↓, 2,   EMT↓, 2,   ERK↓, 3,   p‑ERK↓, 2,   FOXO3↑, 1,   p‑GSK‐3β↓, 1,   HDAC2↓, 1,   HDAC3↓, 1,   IGF-1↓, 3,   IGF-1R↓, 2,   IGFBP3↑, 1,   mTOR↓, 4,   p‑mTOR↓, 1,   NOTCH3↓, 1,   PI3K↓, 5,   PTEN↑, 2,   STAT3↓, 5,   TOP1↓, 1,   TOP2↓, 1,   TumCG↓, 5,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 1,   Ca+2↓, 1,   Ca+2↑, 1,   cal2↑, 1,   CD31↓, 1,   E-cadherin↑, 1,   FAK↓, 2,   ITGB4↓, 1,   Ki-67↓, 2,   MMP1↓, 1,   MMP2↓, 3,   MMP9↓, 4,   MMPs↓, 1,   N-cadherin↓, 1,   PDGF↓, 1,   PKCδ↓, 1,   STAC2↓, 1,   TGF-β↓, 1,   TIMP1↑, 1,   TumCI↓, 5,   TumCMig↓, 3,   TumCP↓, 8,   TumMeta↓, 3,   Twist↓, 2,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   EGFR↓, 3,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 7,   NO↓, 2,   NO↑, 1,   VEGF↓, 5,   VEGFR2↓, 1,   VM↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 5,   GLUT3↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   CRP↓, 1,   HCAR1↓, 1,   IFN-γ↓, 1,   IL1β↓, 2,   IL6↓, 3,   Inflam↓, 1,   IRAK4↓, 1,   JAK↓, 1,   NF-kB↓, 10,   p65↓, 1,   PD-L1↓, 2,   PGE2↓, 1,   PSA↓, 1,   T-Cell↝, 1,   TLR4↓, 1,   TNF-α↓, 2,  

Cellular Microenvironment ⓘ

NOX↓, 1,   pH↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 2,   ChemoSen↑, 5,   CYP1A2↓, 1,   Dose?, 1,   Dose↓, 1,   Dose↑, 2,   Dose↝, 1,   Dose∅, 1,   eff↓, 2,   eff↑, 15,   Half-Life↝, 1,   P450↓, 1,   RadioS↑, 2,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,   CRP↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 3,   HER2/EBBR2↓, 2,   IL6↓, 3,   Ki-67↓, 2,   LDH↓, 3,   PD-L1↓, 2,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoP↑, 2,   neuroP↑, 2,   Risk↓, 1,   TumVol↓, 1,   Weight↓, 1,  
Total Targets: 259

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 4,   GPx↑, 1,   GSH↑, 5,   GSR↑, 1,   GSTA1↑, 1,   GSTs↑, 1,   HO-1↑, 1,   lipid-P↓, 2,   MDA↓, 4,   NQO1↑, 1,   NRF2↑, 3,   ROS↓, 7,   SOD↑, 4,  

Metal & Cofactor Biology ⓘ

IronCh↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   mitResp↑, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 2,   adiP↑, 1,   ALAT↓, 2,   AMPK↑, 2,   FABP4↓, 1,   FAO↑, 1,   FASN↓, 7,   glucose↓, 1,   LDL↓, 1,   PGM1?, 1,   PKM2↓, 1,   PPARγ↓, 1,   p‑PPARγ↓, 1,   SREBP1↓, 3,  

Cell Death ⓘ

MAPK↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

CEBPA↓, 1,   FGF↑, 1,  

Migration ⓘ

AntiAg↑, 1,   Ca+2?, 1,   Ca+2↓, 1,   CEA↓, 1,   Ki-67↓, 1,   MMP2↓, 1,   MMP2↑, 1,   PKA↑, 1,   PKCδ↓, 1,   ROCK1↓, 1,   TGF-β↓, 2,   α-SMA↝, 1,   β-catenin/ZEB1↑, 1,  

Barriers & Transport ⓘ

BBB↝, 1,   GLUT4↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   ICAM-1↓, 1,   IL18↓, 1,   IL1β↓, 1,   IL22↓, 1,   IL6↓, 2,   IL8↓, 2,   Inflam↓, 7,   NF-kB↓, 2,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

tau↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↝, 1,   Dose↑, 2,   Dose↝, 2,   eff↑, 1,   Half-Life↝, 2,   P450↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   AST↓, 3,   CEA↓, 1,   IL6↓, 2,   Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 4,   chemoP↑, 2,   cognitive↑, 1,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 2,   radioP↑, 1,   toxicity∅, 2,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 86

Scientific Paper Hit Count for: FASN, Fatty acid synthase
4 Orlistat
2 alpha Linolenic acid
2 Ashwagandha(Withaferin A)
2 Citric Acid
2 Curcumin
2 Luteolin
2 Oleuropein
2 Quercetin
2 Resveratrol
2 Sulforaphane (mainly Broccoli)
2 Silymarin (Milk Thistle) silibinin
1 Andrographis
1 Apigenin (mainly Parsley)
1 Betulinic acid
1 Boron
1 Caffeic acid
1 Metformin
1 Capsaicin
1 Docosahexaenoic Acid
1 Emodin
1 Gallic acid
1 Ginkgo biloba
1 HydroxyCitric Acid
1 Lycopene
1 Mushroom Chaga
1 Oroxylin-A
1 HydroxyTyrosol
1 Propolis -bee glue
1 Pterostilbene
1 Rutin
1 Shikonin
1 Ursolic acid
1 Vitamin B5,Pantothenic Acid
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:931  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page